Analyst Call of the Year: Collins Stewart on Encysive (ENCY)
Normally, Wall Street analysts get beat up in the media for their bad calls. So today we wanted to highlight an outstanding call by an analyst.
The stock: Encysive Pharmaceuticals Inc. (Nasdaq: ENCY).
The analyst: Andrew Fein at Collins Stewart
Yesterday, Fein upgraded Encysive to Buy. Today, the company announced a deal to be acquired by Pfizer (NYSE: PFE) for $2.35 per share, a huge premium to yesterday's $1.08 close. If you followed Fein's advice and bought the stock yesterday before the close you would be up over 100% today. Friday's close was $0.85, so if you bought yesterday morning, after the call, you would be up even more.
Fein was positive on Encysive's pulmonary hypertension drug THELIN in the EU and potential US approval. Pfizer saw the same thing and jumped at the chance to buy the entire company.
Great Call!
Some other pharmaceutical stocks Fein has Buy ratings on: Inspire Pharmaceuticals, Inc. (Nasdaq: ISPH), United Therapeutics Corp. (Nasdaq: UTHR), Array BioPharma, Inc. (Nasdaq: ARRY), GTC Biotherapeutics, Inc. (Nasdaq: GTCB), OSI Pharmaceuticals Inc. (Nasdaq: OSIP), Tercica Inc. (Nasdaq: TRCA), Metabasis Therapeutics Inc. (Nasdaq: MBRX), Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC), Rosetta Genomics, Ltd. (Nasdaq: ROSG), Insmed Incorporated (Nasdaq: INSM), Hana Biosciences Inc. (Nasdaq: HNAB), Allos Therapeutics, Inc. (Nasdaq: ALTH), Sunesis Pharmaceuticals Inc. (Nasdaq: SNSS).
Create E-mail AlertRelated Categories
Insiders' BlogTrader Talk
Stocks Mentioned
-0.06
+0.06Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
